Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular pathogenesis of chronic myeloid leukemia

Molecular pathogenesis of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular pathogenesis of chronic myeloid leukemia

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/molecular-pathogenesis-of-chronic-myeloid-leukemia-C4JNMyS7Ay
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0294-0
Publisher site
See Article on Publisher Site

Abstract

Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 10, 2016

References

  • Chronic myeloid leukemia: reminiscences and dreams
    Mughal, TI; Radich, JP; Deininger, MW; Apperley, JF; Hughes, TP; Harrison, CJ
  • How do Abl family kinases regulate cell shape and movement?
    Hernández, SE; Krishnaswami, M; Miller, AL; Koleske, AJ
  • Molecular biology of bcr-abl1-positive chronic myeloid leukemia
    Quintás-Cardama, A; Cortes, J
  • Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    Ren, R
  • Structure of the Bcr-Abl oncoprotein oligomerization domain
    Zhao, X; Ghaffari, S; Lodish, H; Malashkevich, VN; Kim, PS
  • The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl
    Zhang, X; Subrahmanyam, R; Wong, R; Gross, AW; Ren, R
  • Chronic myeloid leukemia – some topical issues
    Mughal, T; Cortes, J; Cross, NCP; Donato, N; Hantschel, O; Jabbour, E
  • Acute leukaemia in bcr/abl transgenic mice
    Heisterkamp, N; Jenster, G; Hoeve, J; Zovich, D; Pattengale, PK; Groffen, J
  • Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
    Lichty, BD; Keating, A; Callum, J; Yee, K; Croxford, R; Corpus, G
  • p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
    Rhee, F; Hochhaus, A; Lin, F; Melo, JV; Goldman, JM; Cross, NC
  • A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice
    Jinawath, N; Norris-Kirby, A; Smith, BD; Gocke, CD; Batista, DA; Griffin, CA
  • Regulation of the c‑Abl and Bcr-Abl tyrosine kinases
    Hantschel, O; Superti-Furga, G
  • Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia – is it all BCR-ABL?
    Rumpold, H; Webersinke, G
  • JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
    Warsch, W; Walz, C; Sexl, V
  • Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
    Xie, S; Wang, Y; Liu, J; Sun, T; Wilson, MB; Smithgall, TE
  • Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
    Samanta, A; Perazzona, B; Chakraborty, S; Sun, X; Modi, H; Bhatia, R
  • The role of myc in transformation by BCR-ABL
    Sawyers, CL
  • JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
    Steelman, LS; Pohnert, SC; Shelton, JG; Franklin, RA; Bertrand, FE; McCubrey, JA
  • Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib
    Ozaki, K-I; Kosugi, M; Baba, N; Fujio, K; Sakamoto, T; Kimura, S
  • Molecular pathways: BCR-ABL
    Cilloni, D; Saglio, G
  • Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia
    Zeng, X; Zhao, H; Li, Y; Fan, J; Sun, Y; Wang, S
  • BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2
    Perrotti, D; Cesi, V; Trotta, R; Guerzoni, C; Santilli, G; Campbell, K
  • miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts
    Eiring, AM; Harb, JG; Neviani, P; Garton, C; Oaks, JJ; Spizzo, R
  • Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
    Deininger, MW; Hodgson, JG; Shah, NP; Cortes, JE; Kim, D-W; Nicolini, FE
  • Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
    Soverini, S; Benedittis, C; Machova Polakova, KM; Linhartova, J; Castagnetti, F; Gugliotta, G
  • Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
    Parker, WT; Ho, M; Scott, HS; Hughes, TP; Branford, S
  • Pushing the limits of targeted therapy in chronic myeloid leukaemia
    O’Hare, T; Zabriskie, MS; Eiring, AM; Deininger, MW
  • Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
    Cross, NCP; White, HE; Ernst, T; Welden, L; Dietz, C; Saglio, G
  • Present and future of molecular monitoring in chronic myeloid leukaemia
    Soverini, S; Benedittis, C; Mancini, M; Martinelli, G
  • Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients
    Alikian, M; Ellery, P; Forbes, M; Gerrard, G; Kasperaviciute, D; Sosinsky, A